Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure

被引：4

作者：

Buyukasik, Yahya ^{[1
]}

机构：

[1] Hacettepe Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey

来源：

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI | 2011年 / 21卷 / 02期

关键词：

Chronic myeloid leukemia; Targeted therapy; Imatinib; Dasatinib; Nilotinib; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL MUTATIONS; CHRONIC-PHASE; FOLLOW-UP; CYTOGENETIC RESPONSES; EUROPEAN LEUKEMIANET; SUBOPTIMAL RESPONSE; DASATINIB; RESISTANT; NILOTINIB;

D O I：

10.4999/uhod.11012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.

引用

页码：4 / 9

页数：6

共 23 条

[1] Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in the Long-Term Outcome of Patients With Early Chronic Myeloid Leukemia in Chronic Phase [J].

Alvarado, Yesid ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Faderl, Stefan ;

Borthakur, Gautam ;

Burger, Jan ;

Wierda, William ;

Garcia-Manero, Guillermo ;

Shan, Jianqin ;

Cortes, Jorge .

CANCER, 2009, 115 (16) :3709-3718

[2] Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[3] Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? [J].

Branford, Susan ;

Melo, Junia V. ;

Hughes, Timothy P. .

BLOOD, 2009, 114 (27) :5426-5435

[4]

CASTAGNETTI F, 2009, HAEMATOLOGICA S2, V94

[5] Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib [J].

Ernst, Thomas ;

Erben, Philipp ;

Mueller, Martin C. ;

Paschka, Peter ;

Schenk, Thomas ;

Hoffmann, Jana ;

Kreil, Sebastian ;

La Rosee, Paul ;

Hehlmann, Rudiger ;

Hochhaus, Andreas .

HAEMATOLOGICA, 2008, 93 (02) :186-192

[6] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib [J].

Hochhaus, A. ;

Baccarani, M. ;

Deininger, M. ;

Apperley, J. F. ;

Lipton, J. H. ;

Goldberg, S. L. ;

Corm, S. ;

Shah, N. P. ;

Cervantes, F. ;

Silver, R. T. ;

Niederwieser, D. ;

Stone, R. M. ;

Dombret, H. ;

Larson, R. A. ;

Roy, L. ;

Hughes, T. ;

Mueller, M. C. ;

Ezzeddine, R. ;

Countouriotis, A. M. ;

Kantarjian, H. M. .

LEUKEMIA, 2008, 22 (06) :1200-1206

[7] Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia [J].

Hochhaus, A. ;

O'Brien, S. G. ;

Guilhot, F. ;

Druker, B. J. ;

Branford, S. ;

Foroni, L. ;

Goldman, J. M. ;

Mueller, M. C. ;

Radich, J. P. ;

Rudoltz, M. ;

Mone, M. ;

Gathmann, I. ;

Hughes, T. P. ;

Larson, R. A. .

LEUKEMIA, 2009, 23 (06) :1054-1061

[8] Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy [J].

Hochhaus, Andreas ;

Kantarjian, Hagop M. ;

Baccarani, Michele ;

Lipton, Jeffrey H. ;

Apperley, Jane F. ;

Druker, Brian J. ;

Facon, Thierry ;

Goldberg, Stuart L. ;

Cervantes, Francisco ;

Niederwieser, Dietger ;

Silver, Richard T. ;

Stone, Richard M. ;

Hughes, Timothy P. ;

Muller, Martin C. ;

Ezzeddine, Rana ;

Countouriotis, Athena M. ;

Shah, Neil P. .

BLOOD, 2007, 109 (06) :2303-2309

[9] Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase [J].

Hughes, Timothy ;

Saglio, Giuseppe ;

Branford, Susan ;

Soverini, Simona ;

Kim, Dong-Wook ;

Mueller, Martin C. ;

Martinelli, Giovanni ;

Cortes, Jorge ;

Beppu, Lan ;

Gottardi, Enrico ;

Kim, Dongho ;

Erben, Philipp ;

Shou, Yaping ;

Haque, Ariful ;

Gallagher, Neil ;

Radich, Jerald ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (25) :4204-4210

[10] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate [J].

Jabbour, E. ;

Kantarjian, H. ;

Jones, D. ;

Talpaz, M. ;

Bekele, N. ;

O'Brien, S. ;

Zhou, X. ;

Luthra, R. ;

Garcia-Manero, G. ;

Giles, F. ;

Rios, M. B. ;

Verstovsek, S. ;

Cortes, J. .

LEUKEMIA, 2006, 20 (10) :1767-1773

← 1 2 3 →